Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Detalles Bibliográficos
Autores principales: Djomkam, Alexandra Lindsey Zune, Olwal, Charles Ochieng', Sala, Theodore Beyeme, Paemka, Lily
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466403/
https://www.ncbi.nlm.nih.gov/pubmed/32974166
http://dx.doi.org/10.3389/fonc.2020.01448
_version_ 1783577805731135488
author Djomkam, Alexandra Lindsey Zune
Olwal, Charles Ochieng'
Sala, Theodore Beyeme
Paemka, Lily
author_facet Djomkam, Alexandra Lindsey Zune
Olwal, Charles Ochieng'
Sala, Theodore Beyeme
Paemka, Lily
author_sort Djomkam, Alexandra Lindsey Zune
collection PubMed
description
format Online
Article
Text
id pubmed-7466403
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74664032020-09-23 Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Djomkam, Alexandra Lindsey Zune Olwal, Charles Ochieng' Sala, Theodore Beyeme Paemka, Lily Front Oncol Oncology Frontiers Media S.A. 2020-08-19 /pmc/articles/PMC7466403/ /pubmed/32974166 http://dx.doi.org/10.3389/fonc.2020.01448 Text en Copyright © 2020 Djomkam, Olwal, Sala and Paemka. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Djomkam, Alexandra Lindsey Zune
Olwal, Charles Ochieng'
Sala, Theodore Beyeme
Paemka, Lily
Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
title Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
title_full Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
title_fullStr Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
title_full_unstemmed Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
title_short Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
title_sort commentary: sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466403/
https://www.ncbi.nlm.nih.gov/pubmed/32974166
http://dx.doi.org/10.3389/fonc.2020.01448
work_keys_str_mv AT djomkamalexandralindseyzune commentarysarscov2cellentrydependsonace2andtmprss2andisblockedbyaclinicallyprovenproteaseinhibitor
AT olwalcharlesochieng commentarysarscov2cellentrydependsonace2andtmprss2andisblockedbyaclinicallyprovenproteaseinhibitor
AT salatheodorebeyeme commentarysarscov2cellentrydependsonace2andtmprss2andisblockedbyaclinicallyprovenproteaseinhibitor
AT paemkalily commentarysarscov2cellentrydependsonace2andtmprss2andisblockedbyaclinicallyprovenproteaseinhibitor

Ejemplares similares